Sort   by:  
 Page size 
ProteomicsEvaluation of phospho-tyrosine antibodies for label-free phosphoproteomics
In the past decade multiple tyrosine kinase inhibitors (TKIs) have been implemented in standard treatment regimens for patients with cancer. Unfortunately the majority of patients develops resistance to these drugs. Reliable tools for analysis of pharmacodynamic effects and drug resistance mechanism...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2016-10-21 | MSV000080270 | MassIVE
TranscriptomicsCharacterising the cellular activity of new Fibroblast Growth Factor Receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
Fibroblast growth factor receptors (FGFRs) can act as driving oncoproteins in certain cancers due to mutation, over-expression or activating gene fusions and are therefore attractive drug targets. Here we have characterized tumour cell responses to three new inhibitors of FGFR1-3, AZ12576089, AZ129...
ORGANISM(S): Homo sapiens 
2012-10-02 | E-TABM-1222 | biostudies-arrayexpress
GenomicsAn East-Asian polymorphism underlies BCR-ABL mutation-independent resistance to tyrosine kinase inhibitors in chronic myelogenous leukemia
We used massively parallel DNA sequencing of paired-end ditags (DNA-PET) to identify structural genetic factors associated with disease progression and drug-resistance in representative samples from four CML patients and one CML cell line. The functional consequences of our genetic findings were ev...
ORGANISM(S): Homo sapiens 
2012-02-27 | E-GEOD-28303 | biostudies-arrayexpress
GenomicsHistologic transformation induced by EGFR tyrosine kinase inhibitors
Histologic transformation induced by EGFR tyrosine kinase inhibitors
PRJNA1145888 | ENA
ProteomicsProbing tyrosine kinase inhibitors specificity
Using a three-pronged MS-based proteomic approach, we assessed the mode-of-action of four clinically-relevant tyrosine kinase inhibitors in an epithelial cancer cell line. Here we defined the: (I) semi-quantitative tyrosine kinome; (II) drug interactome; and (III) drug-induced effects on the tyrosin...
ORGANISM(S): Homo sapiens (Human) 
2014-05-12 | PXD000681 | Pride
Human Tyrosine kinase inhibitors Chemical proteomics Phosphoproteomics Phosphotyrosine Lc-ms/ms 
ProteomicsTotal protein profiles of human induced pluripotent stem cell-derived cardiomyocytes in response to four tyrosine kinase inhibitors
Drug-induced cardiotoxicity is a widespread clinical issue affecting numerous drug classes and remains difficult to treat. One such drug class is Tyrosine Kinase Inhibitors (TKIs), which cause varying degrees of contraction-related cardiotoxicity usually after weeks of exposure. Understanding molecu...
ORGANISM(S): Homo sapiens (Human) 
2019-05-16 | PXD012043 | Pride
Tyrosine kinase inhibitor Cardiotoxicity Aerobic glycolysis Human induced pluripotent stem cell-derived cardiomyocyte Mitochondrial respiration Drug adaptation Tandem mass tag mass spectrometry 
GenomicsTumor-independent host gene expression changes induced by tyrosine kinase inhibitors
Tumor-independent host gene expression changes induced by tyrosine kinase inhibitors
PRJNA446647 | ENA
TranscriptomicsAn Inducible TGF-β2-TGFβR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases
The epidermal growth factor receptor (EGFR) is overexpressed in approximately 90% of head and neck squamous cell carcinomas (HNSCC), and molecularly targeted therapy against the EGFR with the monoclonal antibody cetuximab modestly increases overall survival in head and neck cancer patients. We hypot...
ORGANISM(S): Homo sapiens 
2016-03-22 | E-GEOD-67500 | biostudies-arrayexpress
TranscriptomicsTumor-independent host gene expression changes induced by tyrosine kinase inhibitors
Transcriptome analysis was used to identify tumor-independent changes after treatment with different tyrosine kinase inhibitors (TKIs).
ORGANISM(S): Mus musculus 
2018-03-29 | GSE112466 | GEO
ModelsBouchnita2019 - A multiscale model to design therapeutic strategies that overcome drug resistance to tyrosine kinase inhibitors in multiple myeloma
Drug resistance (DR) is a phenomenon characterized by the tolerance of a disease to pharmaceutical treatment. In cancer patients, DR is one of the main challenges that limit the therapeutic potential of the existing treatments. Therefore, overcoming DR by restoring the sensitivity of cancer cells wo...
2020-01-09 | MODEL1912170004 | BioModels
Sort   by:  
 Page size